Curcumin is quickly becoming a household name and noted to be one of the more potent anti-inflammatory agents amongst the natural therapies. We hear about its application in the treatment of Alzheimer’s, depression, colitis, Crohn’s, arthritis, injuries, hypertension, hypercholesterolemia and so much more.
So is this miracle from nature that mystically miraculous, or is there an underlying reason for such broad activity?
One main reason curcumin can be applied with reasonable effect to treat many of these conditions is because inflammation is a fundamental process or chemistry that is common to most if not every disease we face, and this includes diseases like depression that appears to be far removed from our mainstream notion of inflammation. Most drugs we use to treat disease today are effective at neutralizing this inflammatory activity in target tissues or cells.
Research shows curcumin to be a mildly effective inhibitor of key proteins involved in the escalation of inflammation. As a result, it can be used to take the edge off some of these disorders.
Nevertheless, regular old curcumin (even curcumin 95 per cent) is not reliable and is usually not potent enough to deal with deeply rooted inflammation. Treatment results with curcumin are simply not reliable nor are they precisely repeatable.
The reason is that every curcumin extract is comprised of curcuminoids. Within that 95% extract, three curcuminoids make up the 95 per cent concentration. The problem is extracting these underlying curcuminoid proportions fluctuate and do so even for the same brand from batch to batch or lot to lot.
Our recent research has been focused on separating, isolating and mapping the pharmacology of these curcuminoid components to see how they each contribute to the anti-inflammatory and other subcellular activities that help neutralize disease symptoms.
The findings have led to game-changing insight. These curcuminoids can each have distinct pharmacological activity inside our cells. Even if you are certain you are buying a 95 per cent extract every time, you do not have insight into how the underlying curcuminoid proportions have changed from your previous batch to alter the activity of your curcumin.
Our research shows some of this activity to be synergistic to an intended therapeutic outcome. However, in other situations where the curcuminoid proportions shift it can oppose an intended effect. Sometimes you get a potent 95 per cent extract and other times you get a less effective one.
The amazing knowledge to come out of this pharmaceutical research with these curcuminoids is a clearer understanding of the mechanism by which curcumin delivers its activity. Moreover, it has allowed us to stabilize and create proportions of these underlying curcuminoids that serve our targets with greater precision and make certain this activity is consistent from lot to lot.
The result of this novel standard of curcumin pharmacology that is now patented is BDM30™ – now reliable; more effective, and consistent activity for curcumin that also exceeds 95 per cent concentration. BDM30™ is the new household name.
Franco Cavaleri, BSc, PhDc, is The Rhema Group’s Chief Science Officer and a former competitive bodybuilder. He is also the principal research scientist at Biologic Pharmamedical. Franco Cavaleri is also a former IFBB Mr. North America having practiced the science.
